Slide 1: Summit Therapeutics Q1 2025 Earnings Call
Summit Therapeutics Q1 2025 Earnings Call May 1, 2025 4:30pm ET
Slide 2: Forward Looking Statement
Forward Looking Statement Any statements in this presentation about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s par
Slide 3: Q1 2025 Highlights
Q1 2025 Highlights Ivonescimab Collaborations Enrollment completed Progressing & Expanding: Oct 2024, topline data expected mid-2025 Ivonescimab monotherapy MD Anderson Collab approved in China in 1L NSCLC Two studies are open and PD-L1+; OS HR 0.777 at early enrolling: cSCC and GBM HA-requested int
Slide 4: Ivonescimab Pipeline
Ivonescimab Pipeline Conducted in China Planned and Ongoing Studies Fully Sponsored and Managed by Akeso Sponsored by Summit Therapeutics* Phase III Phase III 2L+ EGFRm 2L+ EGFRm NSCLC: NSCLC: 1L NSCLC: 1L NSCLC: 1L NSCLC: 1L NSCLC: 2L+ NSCLC: Expanding CDP Further Announcements in 2025 1L R/M HNSCC
Slide 5: Ivonescimab Catalysts in 2025
Ivonescimab Catalysts Global in 2025 China Mid-2025 Ivonescimab + Chemo vs. Chemo Ivonescimab vs. Pembrolizumab Ivonescimab + Chemo vs. in 2L+ EGFRm NSCLC in 1L PD-L1+ NSCLC Tislelizumab + Chemo in 1L NSCLC Ivo monotherapy: clinically Ivo + chemo achieved meaningful early OS trend statistically & cl
Slide 6: Ivonescimab + Chemo vs. Pembrolizumab + Chemo
Ivonescimab + Chemo vs. Pembrolizumab + Chemo Summit Sponsored Study Randomized, Double-blind, Phase III Study 1L NSCLC: PD-L1 All-Comers* NCT05899608 Non-Squamous OR Squamous Maintenance Key Inclusion Non-Squamous: • 1L squamous or Ivonescimab + Safety and Survival Follow-up Ivonescimab + Ivonescim
Slide 7: Monotherapy Ivonescimab vs. Pembrolizumab
Monotherapy Ivonescimab vs. Pembrolizumab Summit Sponsored Study Randomized, Double-blind, Phase III Study 1L NSCLC with PD-L1 High Expression NCT067675141 Key Inclusion • 1L squamous or Safety and Survival Follow-up Ivonescimab non-squamous 20 mg/kg Q3W Treatment Until Randomization metastatic NSCL
Slide 8: Ivonescimab Opportunity
Ivonescimab Clinical Trials Ivonescimab Opportunity Goes Beyond Checkpoint Inhibitors (CPI) 2028 Estimated $90B+ CPI TAM 2 $20B+ NSCLC CPI TAM2,3 50+ Approved Indications for 1 PD-(L)1 & VEGF Therapies Approved Anti-VEGF Therapies Approved Anti PD-(L)1 Therapies Approved Anti PD-(L)1 & Anti-VEGF The
Slide 9: Financial Summary
Financial Summary As of March 31, 2025 Cash & Investments : ~$361 Million Current Debt: $0 Common Shares Outstanding: ~742 Million Summit Confidential & Proprietary Information Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than 9 Do Not Copy or Di
Slide 10: Financial Summary Q1'25 vs. Q4'24
Financial Summary Q1’25 vs. Q4’24 (1) Excludes stock-based compensation Summit Confidential & Proprietary Information Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than 10 Do Not Copy or Distribute Presentation Summit Therapeutics Q1 2025 Earnings
Slide 11: Schedule Reconciling Selected Non-GAAP Financial Measures
Schedule Reconciling Selected Non-GAAP Financial Measures Note 1: Stock-based compensation is a non-cash charge and costs calculated for this expense can vary year-over-year depending on the stock price of awards on the date of grant as well as the timing of compensation award arrangements. Summit C
Slide 12: Schedule Reconciling Selected Non-GAAP Financial Measures
Schedule Reconciling Selected Non-GAAP Financial Measures Note 1: Stock-based compensation is a non-cash charge and costs calculated for this expense can vary year-over-year depending on the stock price of awards on the date of grant as well as the timing of compensation award arrangements. Summit C
Slide 13: Summit Therapeutics Q1 2025 Earnings Call
Summit Therapeutics Q1 2025 Earnings Call May 1, 2025 4:30pm ET